secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0000950170-22-015259
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio Q2 net loss $17.6M; Phase 1b RLYB212 shows platelet elimination; CFO to retire
--------------------------------------------------------------------------------

- Net loss $17.6M ($0.57/share) vs $11.1M ($0.49) in Q2 2021 on higher R&D and G&A expenses.
- Cash, equivalents and securities $147.4M as of June 30, 2022; runway into Q1 2024.
- Phase 1b RLYB212 shows rapid elimination of HPA-1a positive platelets; protocol amended for broader dose range.
- Phase 1 RLYB116 on track; initial single-dose data for 30 mg expected Q4 2022.
- CFO Jeffrey Fryer to retire; external search for successor begun.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000095017022015259/0000950170-22-015259-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000095017022015259/rlyb-20220808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015259

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer